We are delighted to announce the shortlist for the 6th Annual Scrip Awards. This year we were impressed with the calibre of the entries and we believe the shortlist, chosen by our judging panel of 19 industry experts, reflects the.....

You are a drug company looking for a new candidate to treat obesity. You hear about a tribe in Africa using a certain plant to suppress hunger when they go on long hunting trips. Sounds like there may be a potential blockbuster for those.....

Greece's pricing committee has delayed publishing a price bulletin which was going to set out the prices for all pharmaceutical products available on the market.

The new price bulletin (for all pharmaceutical products) had been due.....

The US FDA has warned healthcare professionals that Pfizer's antibacterial Tygacil (tigecycline) is associated with an increased risk of mortality compared with other drugs that can be used to treat various serious complications. "The increased risk.....

In a bid to beef up its research pipeline Ipsen, the French speciality pharma company, is paying Santhera Pharmaceuticals €13 million up front for the rights to its adrenergic alpha-2 receptor antagonist fipamezole outside North.....

The NHS in the UK could be could be wasting £100 million on medicines that are never consumed, suggests a study to be presented at the Royal Pharmaceutical Society of Great Britain's annual conference in London next week.

Pharmacist Elmarie.....

There is less than a month to go before money from England's new £50 million cancer drugs fund becomes available, but pharmaceutical companies are still in the dark about how to use the fund to get their drugs to patients.

And after another.....

Roche is mulling over plans to slash its operating costs to cope with "mounting pressures to curb healthcare costs" and to deal with a spate of recent setbacks in its late-stage programmes. It said it would review and analyse its.....

Forbion Capital Partners, the Netherlands-based life sciences-focused venture capitalist, has defied the moribund capital market by raising €190 million for two new funds, FCF I Co-Invest Fund and FCF II. As with Forbion's first fund, FCF I, the.....

ThromboGenic's microplasmin met its primary endpoint – resolution of vitromacular adhesion (VMA) – in patients with the eye disease. The study results, presented at the American Society of Retina Specialists (ASRS) meeting this.....

Takeda has acquired exclusive rights in the US, Canada and Mexico to Orexigen Therapeutics' obesity drug Contrave (bupropion SR plus naltrexone SR).

Japan's largest pharma firm will develop and commercialise the combination product.....

Eisai has begun a clinical trial with a novel monoclonal antibody for Alzheimer's disease, which the firm says is the first potential therapy of its type which selectively binds to and eliminates the amyloid-beta aggregates which are linked to the.....

Ono Pharmaceutical has acquired exclusive development and commercialisation rights in Japan to Concordia Pharmaceuticals' direct Ras inhibitor salirasib, which it will develop initially for pancreatic cancer.

The Japanese firm will pay.....

Pfizer has reiterated its commitment to developing an orphan and rare diseases franchise by acquiring the private US company FoldRx Pharmaceuticals. The two companies did not disclose the financial terms of the acquisition, though Pfizer will make an.....

Indian physicians who were involved in the controversial "superbug" NDM-1 study that was published in Lancet Infectious Diseases last month have been asked to confirm whether they followed various national guidelines and procedures required.....

Index Ventures, the global high tech venture capitalist, has appointed Dr Kevin Johnson as a life sciences partner to enhance its push into developing asset-centric investment strategy. Dr Johnson, who was both a venture adviser and CEO of.....

Celator Pharmaceuticals has raised $20 million in a series D round led by new investor Thomas, McNerney & Partners. Alex Zisson, a partner at the venture capital firm, will join Celator's board.

Proceeds from the financing will.....

The US agency that runs Medicare – the Centers for Medicare and Medicaid Services (CMS) - has scheduled a 17 November advisory panel meeting to consider on-label and off-label use of Dendreon's prostate cancer treatment Provenge.....

Two Scottish university spin-out companies, ImmunoSolv and Grampian BioConsultants (GBC), have merged to combine their expertise in immunology and immuno-technology to avoid becoming a "one-trick pony".

The merged company, which is focused on.....

The small UK biotechnology firm Henderson Morley has filed a notice of intention to call in the administrators following its failure to secure the divestment of its ICVT (Ionic Contra Viral Therapy) portfolio to KMS Therapeutics, resulting.....